- Report
- April 2024
- 80 Pages
Ireland
From €1417EUR$1,500USD£1,205GBP
- Report
- April 2024
- 80 Pages
Japan
From €1417EUR$1,500USD£1,205GBP
- Report
- April 2024
- 80 Pages
Poland
From €1417EUR$1,500USD£1,205GBP
- Report
- March 2025
- 74 Pages
China
From €1700EUR$1,800USD£1,446GBP
- Report
- March 2025
- 111 Pages
China
From €1700EUR$1,800USD£1,446GBP
- Report
- June 2021
- 87 Pages
Global
€20776EUR$22,000USD£17,672GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €20776EUR$22,000USD£17,672GBP
- Report
- January 2019
- 14 Pages
United Kingdom
From €566EUR$599USD£481GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €472EUR$500USD£402GBP
- Report
- May 2024
- 95 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- January 2024
- 77 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- November 2023
- 105 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- October 2023
- 82 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- June 2023
- 87 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- May 2023
- 102 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- April 2023
- 71 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- November 2024
- 89 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- May 2022
- 67 Pages
Global
From €1889EUR$2,000USD£1,607GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more